Federal Employees and GLP-1s in 2027: Required Behavioral Therapy, Higher Costs, and How to Pay Less
Every FEHB and PSHB plan will require documented intensive behavioral therapy before and during weight-loss GLP-1 treatment in 2027, and many plans are raising member costs to 50%. A guide for federal employees, postal workers, and retirees before Open Season ends December 14.
Key points
- For plan year 2027, OPM requires all FEHB and PSHB carriers to see documented participation in an evidence-based intensive behavioral therapy (IBT) program before and during treatment with anti-obesity medications
- Qualifying IBT programs provide 26 or more contact hours over 3 to 12 months; plans must cover 12 to 22 IBT sessions a year, and OPM says attestations alone and app-only or AI-only programs do not satisfy the rule
- OPM did not set a cost-share percentage; the Foreign Service Benefit Plan moves anti-obesity medications to 50% coinsurance, and Federal News Network (Consumers' Checkbook) reports most carriers are moving to 50%
- Checkbook found Wegovy 500% more expensive and Zepbound more than 400% more expensive in SAMBA High for 2027, versus a 13% increase in Compass Rose High; Wegovy costs $655.87 a month through Aetna Direct CDHP drug coverage
- Manufacturer self-pay prices in November 2026 start at $149 a month for the Wegovy pill and Foundayo, $349 for standard Wegovy pen doses, and $299 to $449 for Zepbound KwikPen with timely refills; cash spending does not count toward FEHB deductibles or catastrophic limits
- OPM's Inspector General found GLP-1 spending at two carriers covering 69% of FEHB members rose from $392.8 million in 2019 to $2.6 billion in 2024, including diabetes use
- Medicare-enrolled retirees can use the Medicare GLP-1 Bridge ($50 a month through December 31, 2027) for weight loss if they meet its rules; Part D itself cannot cover drugs used for weight loss alone
- Open Season runs November 9 through December 14, 2026; changes take effect January 1, 2027 for annuitants and PSHB enrollees and January 10, 2027 for most other federal employees
The short version
If you get Wegovy, Zepbound, Foundayo, or another GLP-1 drug for weight loss through a federal health plan, two things change when 2027 coverage starts in January.
First, the Office of Personnel Management (OPM), the agency that runs federal health benefits, will make every carrier in the Federal Employees Health Benefits (FEHB) program and the Postal Service Health Benefits (PSHB) program require documented participation in an intensive behavioral therapy (IBT) program before and during treatment with an anti-obesity medication. IBT is structured coaching on eating, physical activity, and habits. Second, many plans will charge members more for these drugs. The Foreign Service Benefit Plan, for example, is moving anti-obesity medications to 50% coinsurance, which means you pay half the drug's cost.
OPM says the two programs cover about 7.9 million people: federal employees, postal workers, some tribal employees, retirees (OPM calls them annuitants), and their families. Open Season, the yearly window to change plans, runs from Monday, November 9 through Monday, December 14, 2026. If you take a GLP-1 or plan to start one, you have four weeks left to compare plans and cash prices for 2027.
What the behavioral therapy rule requires
OPM set out the rule in Carrier Letter 2026-07, its March 31, 2026 call for 2027 plan proposals, and repeated it in its Open Season highlights. In plain terms:
- Plans must cover the therapy. That includes individual and group IBT and medical nutrition therapy (counseling with a registered dietitian). OPM expects plans to cover 12 to 22 IBT sessions a year, depending on progress.
- A qualifying program is substantial. It provides 26 or more contact hours over 3 to 12 months, and it tracks participation, completion, weight change, and markers such as blood pressure and blood sugar.
- Prior authorization depends on it. Prior authorization is the plan's approval before it pays for a drug. For any anti-obesity medication, the plan must confirm that you took part in IBT before starting and that you keep taking part while on the drug.
- A signed statement is not enough. OPM wrote that "attestation statements alone" from members or doctors about past weight-loss attempts should not bypass the requirement.
- Apps alone do not count. Sessions can be in person or virtual, but OPM excluded smartphone-app-only and AI-only programs. Virtual programs must include human coaching.
Because OPM requires IBT "both prior to and during" treatment, the rule reaches people already on a GLP-1, not only new starts. Kevin Moss, a senior editor at Consumers' Checkbook, wrote in Federal News Network on November 16 that carriers are hiring outside vendors to run the sessions, which he described as virtual and free to members. Your 2027 plan brochure should explain how to sign up.
The cost pressure behind the rule is documented. A December 8, 2025 data brief from OPM's Office of the Inspector General looked at two carriers that cover 69% of FEHB members. Their GLP-1 spending rose from $392.8 million in 2019 to $2.6 billion in 2024, a 554% increase, and GLP-1s grew from 4% to 18% of pharmacy spending. Those figures include GLP-1s prescribed for diabetes as well as weight loss. OPM lists GLP-1s among the reasons enrollee premiums will rise an average of 10.9% in FEHB and 8.2% in PSHB in 2027.
Who the rule covers, and who it may not
OPM's rule is written for anti-obesity medications used to manage obesity. OPM's call letter and Open Season highlights do not list exemptions by diagnosis. Moss wrote that members taking a GLP-1 for type 2 diabetes or severe sleep apnea "should not be required" to go through IBT, and he advised current users to call their plan to find out whether the new prior authorization applies to them.
The diagnosis on your prescription matters because the same drug can carry several approved uses. The FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024. Wegovy is approved to lower the risk of heart attack and stroke in adults with heart disease and obesity or overweight, according to KFF. Ozempic and Mounjaro are approved for type 2 diabetes. If you take one of these drugs for one of those conditions, ask your plan in writing whether the IBT rule and the new cost share apply to your prescription.
OPM still requires every plan to cover at least one GLP-1 anti-obesity medication and at least two oral anti-obesity medications.
What your plan will charge
OPM did not set a cost-share percentage in its call letter or its Open Season highlights. Carriers chose their own. The Foreign Service Benefit Plan's 2027 changes page says covered anti-obesity medications, including GLP-1s prescribed for weight loss, will cost 50% coinsurance with no deductible at in-network retail pharmacies, Express Scripts home delivery, and Smart90 pharmacies. Moss reported that most FEHB carriers are moving to a 50% member cost share.
Checkbook priced the drugs with carrier drug-cost tools and compared 2026 with 2027. In SAMBA High, Moss wrote, Wegovy will be 500% more expensive and Zepbound more than 400% more expensive. Compass Rose High showed a 13% increase for both. In Aetna Direct, a consumer-driven health plan (CDHP), a one-month supply of Wegovy through the plan's drug coverage costs $655.87. Over 12 months that is about $7,870.
Drugmaker savings cards help less than you might expect. Federal anti-kickback law, which keeps these cards away from Medicare and Medicaid patients, excludes the FEHB program from its definition of a federal health care program. Novo Nordisk's Wegovy savings card terms say the FEHB Program is not a federal or state government health care program, so FEHB members whose plan covers Wegovy can use that card. The terms do not name PSHB. Lilly's card terms exclude anyone in a "state, federal, or government funded healthcare program" and do not mention FEHB or PSHB, so ask Lilly whether your plan qualifies. Even then, savings are capped at $100 a month for Novo Nordisk's Wegovy offer and for Lilly's cards for covered Zepbound and Foundayo prescriptions. That would bring the $655.87 Aetna Direct price to about $556. A card also works only after the plan approves the fill, so it does not get you around the IBT requirement. Lilly's posted card terms end December 31, 2026.
Paying cash outside your plan
Both drugmakers sell these drugs directly at fixed cash prices. These were the self-pay prices on the manufacturers' sites in mid-November 2026:
- Wegovy pill: $149 a month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg or 25 mg.
- Wegovy pen: $349 a month for the 0.25 mg through 2.4 mg doses, and $399 for the 7.2 mg Wegovy HD dose.
- Zepbound KwikPen: $299 a month for 2.5 mg and $399 for 5 mg. The 7.5 mg through 15 mg doses cost $449 if you refill within 45 days of your last delivery. Otherwise Lilly's regular price is $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, or 15 mg.
- Foundayo: Lilly's regular prices run from $149 a month for 0.8 mg to $349 for 14.5 mg and 17.2 mg, with purchase offers that lower some doses if you refill on time.
TrumpRx, the federal cash-price website, lists the same starting prices: $149 for the Wegovy pill, $199 for the Wegovy pen, and $299 for Zepbound. Those are starting-dose figures, and higher doses cost more on the drugmakers' sites. OPM asked carriers to tell members about TrumpRx.
Compare the numbers at your dose. The Aetna Direct member paying $655.87 for Wegovy through the plan would pay $349 for the same pen as cash, about $3,680 less over a year. Cash purchases have two trade-offs, Moss noted. You need only a prescription, without the plan's IBT gate, but none of that spending counts toward your plan's deductible or catastrophic limit (the yearly cap on what you pay for covered care). If you expect large medical bills in 2027, running the drug through your plan can help you reach that cap sooner, after which covered care costs you nothing.
You can pay with pre-tax money in some cases. Under IRS Publication 502, prescribed drugs count as medical expenses, and weight-loss costs count when they treat a disease a doctor has diagnosed, such as obesity. FSAFEDS, the federal flexible spending account program, is open only to active employees and requires you to re-enroll every Open Season. OPM says it will add a Visa debit card for health care FSA accounts in 2027. A health savings account (HSA) requires enrollment in a high-deductible health plan. Ask FSAFEDS or your HSA administrator what paperwork they need before you buy.
Retirees with Medicare
FEHB annuitants. Moss counted 43 FEHB plans that will offer a standalone Medicare Part D prescription drug plan in 2027, including Aetna Direct CDHP, APWU High, Blue Cross Blue Shield Basic and Standard, Compass Rose High, GEHA High and Standard, MHBP Standard, and SAMBA High and Standard. In his Aetna Direct example, Wegovy cost $45 a month through Part D compared with $655.87 through the plan's regular drug coverage. One limit applies here. Federal law bars Part D from covering drugs used for weight loss alone, so a Part D plan can pay for Wegovy only for a covered use such as its heart-risk indication, as KFF explains.
PSHB annuitants. Postal retirees who are eligible for Medicare Part D get it automatically through their PSHB plan's employer group plan, at no extra premium, according to OPM. If you opt out of that Part D coverage, you lose PSHB drug coverage while paying the same premium. Many Medicare-eligible postal retirees must also enroll in Medicare Part B to keep PSHB coverage, with exceptions for some people who retired on or before January 1, 2025.
The Medicare GLP-1 Bridge. For weight loss alone, Medicare's route is the GLP-1 Bridge, which charges a $50 monthly copay from July 1, 2026 through December 31, 2027. It covers Foundayo, Wegovy injection or tablet, and only the Zepbound KwikPen. Under Medicare's fact sheet, you need Part D coverage and a qualifying BMI. You also must not have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. If your Part D plan has been paying for a GLP-1 for any reason, you must keep getting it through that plan. The $50 does not count toward your Part D out-of-pocket limit. Moss recommends that annuitants enrolled in Part D look at the Bridge. If your Part D comes through an FEHB or PSHB plan, call 1-800-MEDICARE to confirm you qualify. Our Medicare GLP-1 Bridge guide walks through the BMI tiers and the application steps.
An Open Season checklist
1. Read your plan's 2027 brochure on OPM.gov. Find the anti-obesity medication rules, the coinsurance or copay, and the IBT vendor.
2. Price your exact drug and dose. Use each plan's drug-cost tool for 2027, then compare plans in OPM's Plan Comparison Tool. Postal employees and retirees compare plans in the Postal Service Health Benefits System (PSHBS).
3. Check cash prices at your dose. Multiply the monthly plan price and the self-pay price by 12.
4. Confirm your diagnosis path. If you take a GLP-1 for diabetes, sleep apnea, or heart disease, ask the plan in writing whether IBT and the new cost share apply.
5. If you have Medicare, compare plans that include Part D and check whether you qualify for the Bridge.
6. Re-enroll in FSAFEDS if you want a health care FSA in 2027. It does not carry over on its own.
7. Watch for a closing plan. Nine FEHB plans and one PSHB plan end after 2026. Members who do nothing are moved to Compass Rose Standard (FEHB) or FEP Blue Focus (PSHB), so check those plans' drug rules too.
Open Season changes take effect January 1, 2027 for annuitants and PSHB enrollees and January 10, 2027 for most other federal employees. If the new costs push you toward stopping your GLP-1, read our pieces on why people quit GLP-1 drugs and what to do when an employer drops coverage first.
Limitations
- OPM's documents do not list diagnosis-based exemptions; the statement that members taking GLP-1s for type 2 diabetes or severe sleep apnea should not need IBT comes from Federal News Network, so confirm with your plan
- Plan-by-plan cost changes for SAMBA High, Compass Rose High, and Aetna Direct come from Consumers' Checkbook price checks reported by Federal News Network, not from plan brochures we reviewed; the 50% figure is confirmed here only for the Foreign Service Benefit Plan
- The claim that carrier IBT programs are virtual and free comes from Federal News Network; vendor names, scheduling, and cost may differ by plan
- Manufacturer self-pay prices and savings card terms were checked in mid-November 2026; Lilly's card terms end December 31, 2026, and 2027 terms were not yet posted
- The $45 Part D price for Wegovy in the Aetna Direct example applies only when Part D can cover the drug, such as for its cardiovascular indication; Part D cannot cover weight-loss-only use
- Savings card eligibility depends on each card's terms: Novo Nordisk's Wegovy card terms say FEHB is not a government health care program, but they do not name PSHB, and Lilly's terms do not mention either program
Citations
- 1. Federal Benefits Open Season Highlights, 2027 Plan Yearregulatory U.S. Office of Personnel Management 2026
- 2. FEHB Program Carrier Letter 2026-07: Federal Employees Health Benefits and Postal Service Health Benefits Programs Call Letterregulatory U.S. Office of Personnel Management 2026
- 3. FEHB Program Trends: Increases in Glucagon-like Peptide-1 Receptor Agonists Spending from 2019 to 2024 (Data Brief 2025-CAAG-019)government OPM Office of the Inspector General 2025
- 4. Expect higher prices and stricter approval requirements for weight-loss GLP-1s in FEHB next yearnews Federal News Network 2026
- 5. Federal Employees Health Benefits Program Open Season (FSBP changes for 2027)company AFSPA Foreign Service Benefit Plan 2026
- 6. Postal Service Health Benefits Program Overviewregulatory U.S. Office of Personnel Management 2026
- 7. Medicare GLP-1 Bridgeregulatory CMS 2026
- 8. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234)regulatory Medicare.gov 2026
- 9. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesitypolicy-analysis KFF 2024
- 10. FDA Approves First Medication for Obstructive Sleep Apnearegulatory U.S. Food and Drug Administration 2024
- 11. Wegovy Cost & Coverage Informationcompany Novo Nordisk 2026
- 12. Zepbound Coverage and Savingscompany Eli Lilly and Company 2026
- 13. Foundayo Coverage and Savingscompany Eli Lilly and Company 2026
- 14. TrumpRxgovernment TrumpRx.gov 2026
- 15. Publication 502 (2025), Medical and Dental Expensesregulatory Internal Revenue Service 2026
- 16. 42 U.S. Code 1320a-7b: Criminal penalties for acts involving Federal health care programsStatutory Reference Legal Information Institute
- 17. Wegovy Savings Card Eligibility (NovoCare)manufacturer Novo Nordisk 2026
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.
Related insights
Can Wegovy or Ozempic Make You Fail a Breathalyzer? Ketones, Ignition Interlocks, and False Positives
A November 2026 case report describes a woman with years of sobriety who failed two ignition interlock breath tests days after raising her Wegovy dose. Eating much less can push the body to make a compound that some breath alcohol devices read as alcohol. The evidence is thin, but drivers with interlocks should know how it could happen and what to do.
How to Dispose of Used Ozempic, Zepbound, and Wegovy Pens, Peptide Syringes, and Needles: Sharps Rules in the U.S., UK, and Australia
New York City just raised its fine for loose needles in the trash to $250 after needle-stick injuries among sanitation workers nearly doubled. Here is what goes in a sharps container, what can go in the trash, and how to get rid of a full container where you live.
Can a GLP-1 Replace Your CPAP? Zepbound and Foundayo Cut Sleep Apnea Severity, but Most Patients Still Have the Disease After a Year
Zepbound is approved for obstructive sleep apnea, Lilly's Foundayo pill is headed to the FDA after trials published November 9, 2026, and the experimental drug retatrutide has 80-week sleep apnea results. Here is what the trials found, why most people still need their machine, what happens if you stop, and how coverage works.